Glucocorticoid-induced osteoporosis in men. (Q37881839)

24 August 2017

1 reference

title

Glucocorticoid-induced osteoporosis in men. (English)

1 reference

glucocorticoid-induced osteoporosis

24 August 2017

0 references

1 reference

R A Adler

1

1 reference

PubMed ID

21623147

24 August 2017

M C Hochberg

series ordinal

2

1 reference

24 August 2017

27 May 2011

1 reference

Journal of Endocrinological Investigation

24 August 2017

1 reference

24 August 2017

34

1 reference

24 August 2017

6

1 reference

24 August 2017

481-484

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03346716

24 August 2017

0 references

cites work

Update in male osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Clinical practice. Osteoporosis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Osteoporosis in men: what has changed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Practice patterns in patients at risk for glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Corticosteroid-induced bone loss in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Effects of low-dose prednisone on bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Inhaled corticosteroids and hip fracture: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Male risk factors for hip fracture-a 30-year follow-up study in 7,495 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

The effects of a FRAX revision for the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Residual lifetime risk of fractures in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Osteoporosis in men: the value of laboratory testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Increased Fracture Risk in Patients with Rheumatic Disorders and Other Inflammatory Diseases -- A Case-Control Study with 53,108 Patients with Fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346716

Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease

21 January 2018

1 reference

12 December 2020

Management of glucocorticoid-induced osteoporosis in male veterans

1 reference

12 December 2020

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

1 reference

12 December 2020

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment

1 reference

12 December 2020

Testosterone therapy in glucocorticoid-treated men

1 reference

12 December 2020

Screening for osteoporosis: U.S. preventive services task force recommendation statement

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03346716

1 reference

24 August 2017

1 reference

PubMed ID

21623147